A Mobile SMART Exercise Support Program to Improve Fatigue in Lung Cancer Patients - A RCT

Sponsor
The University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT05331391
Collaborator
(none)
120
1
2
29
4.1

Study Details

Study Description

Brief Summary

Lung cancer (LC) is a common cancer in the world. Among all symptoms, Fatigue is considered as the most distressing medical condition of LC. Prior studies revealed that physical activity effectively relieve fatigue and related problems. The current study attempt to explore the effectiveness of SMART Exercise Support Program (SES) with the use of mobile instant messaging application, on reducing symptoms such as fatigue, and improving physical activity level, physical fitness performance, sleep quality and habits, and quality of life in advanced lung cancer (ALC) patients.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Brief mobile SMART Exercise Support Program
N/A

Detailed Description

Lung cancer (LC) is the most and second most common cancer globally and locally, respectively. Nearly half of LC patients are diagnosed in the advanced stage. Fatigue is perceived to be the most distressing symptom. Physical activity has been proposed as an alternative treatment to relieve fatigue and related problems.

Mobile instant messaging applications (e.g. WhatsApp/WeChat) are popular and inexpensive for interactive messaging. A systematic review showed a majority of messaging interventions were effective in diabetes self-management, weight loss, physical activity (PA), smoking cessation, and medication adherence.

The proposed randomized controlled trial (RCT) aims to examine the effectiveness of SES on relieving fatigue, pain, dyspnea, happiness, anxiety and depression symptoms, physical activity level, physical fitness performance, sleep quality and habits, and quality of life in ALC patients (SES group), compared to the General Hygiene Information (GHI, control) group.

Questionnaires and simple fitness tests will be used at baseline, 6-week, and 24-week assessments. Qualitative feedback will be obtained at the completion of the trial.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The Experimental group will receive a brief SMART Exercise individual face-to-face session, and a package of information on lifestyle-integrated exercise and physical activity delivered through instant messaging and telephone calls. The Control group will receive a face-to-face individual session on general hygiene (GH) information, and a package of information on GH delivered through instant messaging and telephone calls.The Experimental group will receive a brief SMART Exercise individual face-to-face session, and a package of information on lifestyle-integrated exercise and physical activity delivered through instant messaging and telephone calls. The Control group will receive a face-to-face individual session on general hygiene (GH) information, and a package of information on GH delivered through instant messaging and telephone calls.
Masking:
Single (Outcomes Assessor)
Masking Description:
The outcome assessor did not aware of which groups the patients belongs to.
Primary Purpose:
Supportive Care
Official Title:
A Brief Mobile SMART Exercise Support Program to Improve Fatigue in Patients With Advanced Lung Cancer - A Pragmatic Randomized Controlled Trial With Outcome and Process Evaluation
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Brief mobile SMART Exercise Support Program

Patients will receive a brief SMART Exercise individual session with instant messages and telephone coaching for exercise habit formation and maintenance.

Behavioral: Brief mobile SMART Exercise Support Program
Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.

Placebo Comparator: General Hygiene Information (GHI)

Patients will receive an individual session, instant messages and telephone coaching regarding general hygiene information.

Behavioral: Brief mobile SMART Exercise Support Program
Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.

Outcome Measures

Primary Outcome Measures

  1. Change in fatigue level [Baseline and 6 weeks]

    Measured by a 13-item Functional Assessment of Cancer Therapy - Fatigue subscale. The level of fatigue is measured on a five-point Likert scale. The scale range is 0 to 52, with 0 being the worst possible score and 52 being the best possible score indicating no fatigue.

Secondary Outcome Measures

  1. Change in fatigue level [Baseline and 6 months]

    Measured by a 13-item Functional Assessment of Cancer Therapy - Fatigue subscale. The level of fatigue is measured on a five-point Likert scale. The scale range is 0 to 52, with 0 being the worst possible score and 52 being the best possible score indicating no fatigue.

  2. Change in anxiety symptoms [Baseline, 6 weeks, 6 months]

    Measured by a 7-item Generalised Anxiety Disorder Assessment. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 21. The higher scores the greater severity of anxiety symptoms.

  3. Change in depression symptoms [Baseline, 6 weeks, 6 months]

    Measured by a 9-item Patient Health Questionaire. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 27. The higher scores the greater severity of depression symptoms.

  4. Change in physical activity level [Baseline, 6 weeks, 6 months]

    Measured the days and duration of physical activity level and sitting time in the past 7 days by the International Physical Activity Questionnaire (short version) with 4 questions.

  5. Change in sleep quality [Baseline, 6 weeks, 6 months]

    Measured by 7-item Severe Insomnia Index. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 28. The higher scores the greater severity of insomnia.

  6. Change in health-related quality of life [Baseline, 6 weeks, 6 months]

    Measured by a 30-item European Organization for Research and Treatment of Cancer and Lung Module. It contains five functioning scales (physical, social, role, cognitive, and emotional functioning), and eight symptom scales (fatigue, nausea/vomiting, pain, dyspnea, sleep disturbances, appetite loss, constipation, and diarrhoea), and financial impact, and overall quality of life. All scale scores are linearly converted to a range from 0 to 100. Higher scores indicate better functioning for the functioning scales and global QOL; for the symptom scales, higher scores indicate higher symptom burden.

  7. Change in happiness level [Baseline, 6 weeks, 6 months]

    Measured by 4-item Subjective Happiness Scale with a 7-point Likert scale. Total scores range from 4 to 28. The highest scores reflect greater happiness.

  8. Change in cancer-related symptoms [Baseline, 6 weeks and 6 months]

    Measured by 3 items of the Edmonton Symptom Assessment System Scale. The severity at the time of assessment of each symptom is rated from 0 to 10 on a numerical scale, 0 meaning that the symptom is absent and 10 that it is of the worst possible severity.

  9. Change in acceptance of illness [Baseline, 6 weeks and 6 months]

    Measured by a 5-item subscale of Peace, Equanimity, and Acceptance in the Cancer Experience questionnaire

  10. Change in exercise self-efficacy [Baseline, 6 weeks and 6 months]

    Measured by a question with a scale from 0 to 10; "0" indicates no exercise self-efficacy, while "10" indicates highest level of exercise self-efficacy.

  11. Change in social and family support [Baseline, 6 weeks and 6 months]

    Measured by 8-item family and friend subscales of multidimensional Scale of Perceived Social Support with a 7-point Likert scale. Each scale ranges from 4 to 28. A higher score equates with higher social support.

  12. Change in grip strength [Baseline, 6 weeks and 6 months]

    Measured by a dynamometer

  13. Change in lower limb strength [Baseline, 6 weeks, and 6 months]

    Measured by 30-second chair stand test.

  14. Change in balance [Baseline, 6 weeks and 6 months]

    Measured by single-leg-stance test

  15. Change in flexibility [Baseline, 6 weeks, and 6 months]

    Measured by chair sit and reach test

  16. Change in objective physical activity levels, including duration, frequency and intensity [Baseline, 6 weeks, and 6 months]

    Measured by a waist-worn accelerometer

  17. Change in sleep and wake intervals [Baseline, 6 weeks , and 6 months]

    Measured by watch-like activity monitor

  18. Change in exercise capacity [Baseline, 6 weeks and 6 months]

    Measured by a 6-min walk test

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 18 years and above;

  • Diagnosis of Stage III or IV non-small cell lung cancer;

  • Edmonton Symptom Assessment System Scale fatigue symptom score ≥4 out of 10

  • Self-reported engagement of <150 minutes of moderate intensity PA each week,

  • Ambulatory and capable of all self-care activities (European Co-operative Oncology Group (ECOG) Performance Status of ≤2)

  • Either undergoing or finished oncology therapy, biological agents and/or support care;

  • Mentally, cognitively and physically fit to join the trial as determined by the doctor in-charge and responsible clinical investigators;

  • Able to speak and read Chinese;

  • Willing to complete the patient-reported outcome questionnaire;

  • Completion of the Physical Activity Readiness Questionnaire; and

  • Possession of a smartphone with instant messaging functions such as WhatsApp or WeChat.

Exclusion Criteria:
  • Those preparing for lung operation;

  • Skeletal fragility;

  • Serious active infection;

  • Inability to walk;

  • Previously untreated symptomatic brain metastases;

  • Severe respiratory insufficiency;

  • Uncontrolled pain; or

  • Diagnosed psychiatric illness with or without medication such as major depressive disorder.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Queen Mary Hospital Hong Kong Hong Kong

Sponsors and Collaborators

  • The University of Hong Kong

Investigators

  • Principal Investigator: Agnes YK Lai, PhD, School of Nursing, The University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dr. Agnes Yuen-Kwan Lai, Assistant professor, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05331391
Other Study ID Numbers:
  • UW21-148
First Posted:
Apr 15, 2022
Last Update Posted:
Jun 1, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2022